The collaboration with Terray Therapeutics is likely to have a positive impact on BMY's stock in the short term due to the potential expansion of its therapeutic pipeline and the future revenue prospects from commercialization. The deal includes milestone payments and royalties, which are positive financial incentives. However, the actual impact will depend on the success of the compounds developed and the time frame for development and commercialization, which is typically uncertain in the pharmaceutical industry.